Cartas enviadas por José María Azcona a Justo Garate entre 1930 y 1936

7 cartas (mecanografiadas y manuscritas) ; entre 180x130mm y 214x139mm. Ubicación: Caja 1 - Carpeta 82

Cartas enviadas por José María Bengoa a Justo Garate entre 1940 y 1945

10 cartas (mecanografiadas); entre 210x255mm y 210x310mm. [La carta fechada el 10-11-1942 esta incompleta, falta la primera hoja]

Cartas enviadas por José María Bengoa a Justo Garate entre 1947 y 1961

11 cartas (mecanografiadas y manuscritas); entre 170x225mm y 215x275mm

Cartas enviadas por José María Bengoa a Justo Garate entre 1962 y 1992

8 cartas (mecanografiadas y manuscritas); entre 150x210mm y 215x275mm .- 1 Felicitación de Navidad (manuscrita y sin fecha) ; 110mmx160mm

Cartas enviadas por María Milagros Bidegain a Justo Garate entre 1971 y 1972

2 cartas (mecanografiada y manuscrita); entre 215x155mm y 210x315mm.

Cosméticos María D'uol: Gulliver en el país de los gigantes

Duración (en horas): De 21 a 30 horas Destinatario: Estudiante y Docente

Effect of the A cation size disorder and synthesis conditions on the properties of an iron perovskite series

Póster presentado en The Energy and Materials Research Conference - EMR2015 celebrado en Madrid (España) entre el 25-27 de febrero de 2015

[A_Llodio_Yermo] Documentación geométrica para la puesta en valor y difusión social del Santuario de Santa María del Yermo (Laudio/Llodio, Álava)

[ES] La iglesia de Santa María tiene una planta de unos 22x18 metros y cuenta con tres pórticos (sur, oeste y norte) así como una espadaña exenta. Adyacente al sudeste se encuentra la ermita de Santa Lucía. Las excavaciones arqueológicas de dos zonas de unos 6 x 3 metros en el interior y el exterior de la iglesia sirven como hilo conductor a las jornadas de puertas abiertas al público.

Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-beta 3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis

Background Dipeptidyl-peptidase IV (EC 3.4.14.5) (DPPIV) is a serine peptidase involved in cell differentiation, adhesion, immune modulation and apoptosis, functions that control neoplastic transformation. Previous studies have demonstrated altered expression and activity of tissue and circulating DPPIV in several cancers and proposed its potential usefulness for early diagnosis in colorectal cancer (CRC). Methods and principal findings The activity and mRNA and protein expression of DPPIV was prospectively analyzed in adenocarcinomas, adenomas, uninvolved colorectal mucosa and plasma from 116 CRC patients by fluorimetric, quantitative RT-PCR and immunohistochemical methods. Results were correlated with the most important classic pathological data related to aggressiveness and with 5-year survival rates. Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01). Conclusion/significance 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues. This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients. The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.